# The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow

Study · id `cardio:ct-nct06847568` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06847568](<https://clinicaltrials.gov/study/NCT06847568>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06847568

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT06847568. Randomized; double masking; primary purpose prevention. Start 2024-04-01 (actual); primary completion 2026-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT06847568, source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT06847568, source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)
- Primary completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT06847568, source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)
- Completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT06847568, source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06847568, source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06847568-2025-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow
- Condition: ST Segment Elevation Myocardial Infarction (STEMI)
- Condition: No Reflow Phenomenon
- Intervention (Drug): Adrenaline
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: a0e1cbe7cd0c552282cd874dc04d96ad4610bbe26469c5bd2ee713219a8830e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
